Hasni S, et al. - In order to examine the safety, tolerability, and clinical efficacy of omalizumab in mild to moderate systemic lupus erythematosus (SLE), researchers randomized 16 subjects with SLE and a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥4 and elevated autoreactive IgE antibody levels to receive omalizumab or placebo (2:1) for 16 weeks, followed by 16 weeks of open-label treatment and a 4-week washout period. As per outcomes, the subjects well-tolerated omalizumab and showed improvement in disease activity in correlation to omalizumab receipt.